Veerle Bossuyt

5.8k total citations
60 papers, 1.8k citations indexed

About

Veerle Bossuyt is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Veerle Bossuyt has authored 60 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 29 papers in Cancer Research and 16 papers in Molecular Biology. Recurrent topics in Veerle Bossuyt's work include Breast Cancer Treatment Studies (23 papers), Breast Lesions and Carcinomas (15 papers) and HER2/EGFR in Cancer Research (14 papers). Veerle Bossuyt is often cited by papers focused on Breast Cancer Treatment Studies (23 papers), Breast Lesions and Carcinomas (15 papers) and HER2/EGFR in Cancer Research (14 papers). Veerle Bossuyt collaborates with scholars based in United States, Germany and Hungary. Veerle Bossuyt's co-authors include Donald R. Lannin, David L. Rimm, Christian P. Nixon, Jason R. Brown, Lajos Pusztai, Hallie Wimberly, Malini Harigopal, Kurt A. Schalper, Herbert Haack and Matthew R. Silver and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Veerle Bossuyt

57 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Veerle Bossuyt United States 18 1.1k 776 343 341 316 60 1.8k
Konstantinos Tryfonidis Belgium 20 1.1k 1.1× 771 1.0× 233 0.7× 202 0.6× 326 1.0× 53 1.7k
Renaud Sabatier France 24 1.4k 1.3× 645 0.8× 250 0.7× 394 1.2× 675 2.1× 129 2.5k
Luc Cabel France 24 1.2k 1.1× 924 1.2× 213 0.6× 236 0.7× 487 1.5× 81 1.9k
Marie‐Christine Mathieu France 25 978 0.9× 705 0.9× 445 1.3× 160 0.5× 461 1.5× 63 2.1k
Anna Marie Mulligan Canada 25 879 0.8× 715 0.9× 518 1.5× 134 0.4× 579 1.8× 56 1.8k
Gabriella Mariani Italy 19 1.2k 1.1× 831 1.1× 228 0.7× 215 0.6× 464 1.5× 54 1.9k
Naoki Niikura Japan 26 1.7k 1.6× 918 1.2× 284 0.8× 189 0.6× 330 1.0× 147 2.5k
Séverine Guiu France 24 1.1k 1.1× 751 1.0× 168 0.5× 124 0.4× 399 1.3× 78 1.9k
Oleg Gluz Germany 23 1.5k 1.5× 1.1k 1.5× 295 0.9× 184 0.5× 625 2.0× 142 2.4k
Helena R. Chang United States 27 955 0.9× 1.1k 1.4× 498 1.5× 161 0.5× 683 2.2× 69 2.3k

Countries citing papers authored by Veerle Bossuyt

Since Specialization
Citations

This map shows the geographic impact of Veerle Bossuyt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veerle Bossuyt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veerle Bossuyt more than expected).

Fields of papers citing papers by Veerle Bossuyt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veerle Bossuyt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veerle Bossuyt. The network helps show where Veerle Bossuyt may publish in the future.

Co-authorship network of co-authors of Veerle Bossuyt

This figure shows the co-authorship network connecting the top 25 collaborators of Veerle Bossuyt. A scholar is included among the top collaborators of Veerle Bossuyt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veerle Bossuyt. Veerle Bossuyt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Winchester, David J., Stephen B. Edge, Kimberly H. Allison, et al.. (2025). Novel Postneoadjuvant Prognostic Breast Cancer Staging System. Journal of Clinical Oncology. 43(17). 1948–1960. 3 indexed citations
2.
Boyraz, Bariş, Claire Crowley, Mansi A. Saksena, et al.. (2025). Papillary Neoplasms of the Breast: WHO Classification, Multimodality Imaging, and Radiologic-Pathologic Correlation. Radiographics. 45(8). e240091–e240091.
3.
4.
Ho, Alice Y., Stephen L. Shiao, Jonathan Chen, et al.. (2024). PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal of Clinical Oncology. 42(36). 4282–4293. 6 indexed citations
5.
Koh, Siang‐Boon, Brian N. Dontchos, Veerle Bossuyt, et al.. (2021). Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. npj Precision Oncology. 5(1). 85–85. 4 indexed citations
6.
Jimenez, Rachel, Mark L. Zangardi, Geoffrey Fell, et al.. (2020). The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. Journal of Oncology Pharmacy Practice. 27(8). 1883–1890. 3 indexed citations
7.
Székely, Borbála, Veerle Bossuyt, Xiaofeng Li, et al.. (2018). Immunological differences between primary and metastatic breast cancer. Annals of Oncology. 29(11). 2232–2239. 240 indexed citations
8.
Hofstatter, Erin, Steve Horvath, D. Dalela, et al.. (2018). Increased epigenetic age in normal breast tissue from luminal breast cancer patients. Clinical Epigenetics. 10(1). 112–112. 37 indexed citations
9.
Raza, Anwar, et al.. (2017). Hemangioma, Cavernous Liver. StatPearls.
10.
Chagpar, Anees B., Nina Horowitz, Brigid K. Killelea, et al.. (2016). Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients. Annals of Surgery. 265(1). 39–44. 16 indexed citations
11.
Timms, Kirsten M., Anees B. Chagpar, Vikram B. Wali, et al.. (2016). Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer. Clinical Cancer Research. 23(5). 1193–1199. 26 indexed citations
12.
Varadan, Vinay, Hannah Gilmore, Kristy Miskimen, et al.. (2016). Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. Clinical Cancer Research. 22(13). 3249–3259. 75 indexed citations
13.
Bossuyt, Veerle & W. Fraser Symmans. (2016). Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy. Annals of Surgical Oncology. 23(10). 3153–3161. 18 indexed citations
14.
Varadan, Vinay, Sitharthan Kamalakaran, Hannah Gilmore, et al.. (2015). Brief‐exposure to preoperative bevacizumab reveals a TGF‐β signature predictive of response in HER2‐negative breast cancers. International Journal of Cancer. 138(3). 747–757. 14 indexed citations
15.
Brown, Jason R., Hallie Wimberly, Donald R. Lannin, et al.. (2014). Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical Cancer Research. 20(23). 5995–6005. 129 indexed citations
16.
Wimberly, Hallie, Jason R. Brown, Kurt A. Schalper, et al.. (2014). PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunology Research. 3(4). 326–332. 312 indexed citations
17.
18.
Gwin, Katja, Darren Wheeler, Veerle Bossuyt, & Fattaneh A. Tavassoli. (2009). Breast Carcinoma With Chondroid Differentiation: A Clinicopathologic Study of 21 Triple Negative (ER−, PR−, Her2/neu−) Cases. International Journal of Surgical Pathology. 18(1). 27–35. 16 indexed citations
19.
Bossuyt, Veerle, Fabíola Medeiros, Ronny Drapkin, et al.. (2008). Adenofibroma of the Fimbria: A Common Entity That Is Indistinguishable From Ovarian Adenofibroma. International Journal of Gynecological Pathology. 27(3). 390–397. 11 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Konstantinos Tryfonidis Breakdown of academic impact, for papers by Renaud Sabatier Breakdown of academic impact, for papers by Luc Cabel Breakdown of academic impact, for papers by Marie‐Christine Mathieu Breakdown of academic impact, for papers by Anna Marie Mulligan Breakdown of academic impact, for papers by Gabriella Mariani Breakdown of academic impact, for papers by Naoki Niikura Breakdown of academic impact, for papers by Séverine Guiu Breakdown of academic impact, for papers by Oleg Gluz Breakdown of academic impact, for papers by Helena R. Chang
Rankless by CCL
2026